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Abstract
Beta-lactam antibiotics target penicillin-binding proteins including several enzyme
classes essential for bacterial cell-wall homeostasis. To better understand the
functional and inhibitor-binding specificities of penicillin-binding proteins from the
pathogen, Mycobacterium tuberculosis, we carried out structural and phylogenetic
analysis of two predicted D,D-carboxypeptidases, Rv2911 and Rv3330.
Optimization of Rv2911 for crystallization using directed evolution and the GFP
folding reporter method yielded a soluble quadruple mutant. Structures of optimized
Rv2911 bound to phenylmethylsulfonyl fluoride and Rv3330 bound to meropenem
show that, in contrast to the nonspecific inhibitor, meropenem forms an extended
interaction with the enzyme along a conserved surface. Phylogenetic analysis
shows that Rv2911 and Rv3330 belong to different clades that emerged in
Actinobacteria and are not represented in model organisms such as Escherichia
coli and Bacillus subtilis. Clade-specific adaptations allow these enzymes to fulfill
distinct physiological roles despite strict conservation of core catalytic residues. The
characteristic differences include potential protein-protein interaction surfaces and
specificity-determining residues surrounding the catalytic site. Overall, these
structural insights lay the groundwork to develop improved beta-lactam
therapeutics for tuberculosis.
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Introduction
Mycobacterium tuberculosis (Mtb), the etiologic agent of tuberculosis (TB),
presents major threats to public health worldwide [1]. Emergence of Mtb strains
resistant to the front-line and second-line drugs underscores the necessity of
developing new therapeutics [2]. The mycobacterial cell wall, a complex structure
responsible for mediating Mtb interactions with the environment, is a validated
drug target [3]. The cell wall consists of several layers: peptidoglycan,
arabinogalactan, mycolic acids, and the polysaccharide capsule [4]. Key anti-TB
drugs target the biosynthesis of arabinogalactan and mycolic acids [3]. Beta-
lactams, antibiotics that target peptidoglycan biosynthesis and are effective against
diverse bacterial pathogens, have not yet been deployed against Mtb due to the
presence of an efficient beta-lactamase. Nonetheless, a combination of
meropenem, a beta-lactam, and clavulanate, a beta-lactamase inhibitor, is being
tested as a treatment for both active and latent TB [5]. Genetic, biochemical, and
structural characterization of enzymes involved in peptidoglycan homeostasis is
critical for development of this and other new therapeutics.
Peptidoglycan, which forms the membrane-proximal layer of the mycobacterial
cell wall, is composed of repeating disaccharide-pentapeptide units that form
polysaccharide chains covalently crosslinked through the stem peptides [6]. In
Mtb, the disaccharide is N-acetyl glucosamine N-glycolyl or N-acetyl muramic
acid [7], and the pentapeptide attached to the lactate moiety of muramic acid is L-
Ala-iso-D-Glu-meso-DAP-D-Ala-D-Ala (DAP stands for diaminopimelic acid)
that is typically amidated on the free carboxyl groups of iso-D-Glu and DAP [8].
Beta-lactams inhibit several enzyme classes that catalyze different reactions on
peptidoglycan substrates. These penicillin-binding proteins (PBPs) include D,D-
transpeptidases, which crosslink the third and fourth amino acids in the
pentapeptide stems (3–4 crosslinks) [9]. In addition to the synthetic enzymes,
PBPs include hydrolytic D,D-carboxypeptidases and D,D-endopeptidases.
Beta-lactams, including meropenem, mimic the terminal D-Ala-D-Ala dipep-
tide of the stem peptide and act as suicide inhibitors of penicillin-binding proteins
(Fig. 1A). The reaction mechanisms of biosynthetic and hydrolytic penicillin-
binding proteins share the first step. Attack of a serine nucleophile on the peptide
bond between the two D-alanines of the donor stem leads to acylation of the
enzyme by the penultimate D-Ala (position 4 in the stem peptide) and the release
of the terminal D-Ala (Fig. 1B). Transpeptidases use a D-Ala-like distal end of the
DAP residue (position 3 in the stem peptide) of the acceptor stem as a nucleophile
to resolve the covalent intermediate, creating a 4-3 crosslink. In contrast,
carboxypeptidases use a water molecule to resolve the acyl-enzyme intermediate,
converting a pentapeptide stem to a tetrapeptide. Tetrapeptide formation not only
regulates the degree of peptidoglycan crosslinking, but also provides substrate for
the synthesis of 3-3 crosslinks essential for various physiological adaptations [10].
Compared to many beta-lactams, carbapenems appear to have a broader
specificity. Meropenem, for example, is effective against penicillin-binding
proteins as well as L,D-transpeptidases [11], an unrelated family of enzymes that
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form the 3-3 crosslinks. Investigation of changes in Mtb peptidoglycan structure
in response to meropenem treatment suggested that the inhibitor not only blocks
the transpeptidases that synthesize the peptidoglycan crosslinks, but also the
carboxypeptidases, which trim the terminal D-Ala to form tetrapeptides [12].
Fig. 1. Activity and phylogeny of Rv2911 and Rv3330. A. The beta-lactam, meropenem, contains a D-Ala-like group (red) and irreversibly acylates
penicillin-binding proteins, including Rv2911 and Rv3330. B. Enzyme acylation by peptidoglycan stem peptide, the first step in peptidoglycan carboxy- and
trans-peptidation, highlighting the similarity of the terminal D-Ala leaving group (red) and the D-Ala-like acceptor moiety of DAP (purple). C. Neighbor-joining
tree of Peptidase_S11 family proteins of Actinobacteria fall into several clades. Of the two mycobacterial clades, Clade 1 (orange) contains Rv2911, and
Clade 2 (blue) contains Rv3330. E. coli and B. subtilis Peptidase_S11 enzymes (green) form an out-group with several actinobacterial sequences. D.
Maximum-likelihood tree of Peptidase_S11 proteins from select mycobacterial species, Corynebacterium diphtheriae, E. coli, and B. subtilis. High
bootstrapping values confirm the separation of mycobacterial sequences into two distinct clades.
doi:10.1371/journal.pone.0116249.g001
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Of the 11 predicted Mtb penicillin-binding proteins [9], only the synthetic
enzyme PbpA (Rv0016c) has been structurally characterized [13]. The two
penicillin-binding proteins in the Peptidase_S11 Pfam family, Rv2911 (DacB2,
UniProtKB Q7D6F2) and Rv3330 (DacB1, UniProtKB O53380), have recently
been investigated for their potential role as major D,D-carboxypeptidases of Mtb
[12]. Rv2911 is detected in Mtb culture filtrates [14]. Deletion and overexpression
of rv2911 are tolerated in culture [15]. Rv3330 and Rv2911 both demonstrate
specificity for DAP-containing stem peptides [12].
To define the features that mediate inhibitor binding, we determined the crystal
structures of a quadruple-mutant of Rv2911 in complex with a non-specific
inhibitor phenylmethylsulfonyl fluoride (PMSF) and Rv3330 in complex with
meropenem. The Rv3330-meropenem complex highlights an extended interaction
surface that is distinct from that engaged by a donor peptide. Neither enzyme
shows a strong binding affinity for peptidoglycan. In addition, the Rv2911 and
Rv3330 structures reveal subfamily-specific conserved surfaces that distinguish
these enzymes and are consistent with distinct functions in peptidoglycan
homeostasis.
Results
A search of the Mtb genome for Peptidase_S11 Pfam family proteins (PF00768)
yielded two hits: Rv2911 and Rv3330. Similar searches identified penicillin-
binding proteins 5, 6a, 6b, and 7 in the model Gram-negative bacterium, E. coli,
and DacA, DacB, and DacF in the model Gram-positive bacterium, B. subtilis. The
neighbor-joining tree of unique actinobacterial Peptidase_S11 sequences from the
Pfam database showed at least five separate clades, one of which contained the E.
coli and B. subtilis proteins included in the analysis. All mycobacterial sequences
split into two clades, Clade 1 containing Rv2911 and Clade 2 containing Rv3330
peptidase (Fig. 1C). Bootstrapping analysis of the maximum likelihood tree of
select mycobacterial species showed high confidence values for the two clades
(Fig. 1D). Orthologs of both proteins were found in most sequenced
mycobacteria. One exception was M. leprae, where the rv2911 gene is inactivated.
M. smegmatis and several other mycobacteria not only encode an rv3330 ortholog,
but also contain duplications of the rv2911 gene. Based on this analysis, we
concluded that the duplication event that allowed for diversification and
specialization of Rv2911 and Rv3330 likely occurred in a common ancestor of all
mycobacteria.
To investigate the biochemical and structural features of these proteins, we
cloned, expressed in E. coli, and purified Rv2911 and Rv3330 peptidoglycan
peptidases. Sequence analysis indicated that the two proteins share a similar
architecture, containing predicted signal peptides at their N-termini and lacking
the characteristic C-terminal domain of E. coli PBP5 (Fig. 2). A unique feature of
Rv3330 is the presence of a single transmembrane helix at the C-terminus. The
Rv3330 peptidase is thus predicted to be membrane associated, while Rv2911 is a
Mtb Peptidoglycan Peptidases Rv2911 and Rv3330
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periplasmic protein, consistent with its documented presence in Mtb culture
filtrates [14].
Because the wild-type Rv2911 was poorly soluble and failed to crystallize, we
undertook extensive construct optimization using the GFP folding reporter
method [16]. Several rounds of directed evolution to improve solubility yielded
an optimized gene sequence carrying six point mutations. Two of these mutations
were in the predicted signal peptide region, which was truncated in further
optimization. The resulting A113V, T197I, N208D, G289D quadruple-mutant
protein was named Rv2911opt.
The Rv2911opt-PMSF structure was determined at 2.0 A˚ resolution using
multiwavelength anomalous dispersion of Se-labeled enzyme. This structure was
used as the search model to determine the Rv3330-meropenem structure, also at
2.0 A˚ resolution (Table 1). The structures showed similar overall folds containing
two subdomains (Fig. 2). In the first subdomain, the b-sheet core is formed by
strands from both N- and C-terminal sequences. The second subdomain is a-
helical and contains two peripheral two-stranded b-sheets. Structural alignment of
the two peptidases revealed a root-mean-square deviation (RMSD) of 0.76 A˚ over
235 Ca atoms, despite just 46% residue identity over the aligning region. The
extended N-terminal sequences of Rv3330 add an extra strand to the b-sheet and a
short peripheral helix together with a long coil. The Rv3330 C-terminal extension
contains another short helix and extends away from the protein to make a crystal
contact. Remarkably, crystals of both proteins were stabilized by disulfides across
Fig. 2. Structures and domain diagrams of Rv2911opt and Rv3330 enzymes. A. Rv2911opt ribbon diagram showing the inhibitor, PMSF, bound to the
catalytic Ser69 (sticks). Four mutations obtained during split-GFP optimization are highlighted along with two cysteines that participate in intermolecular
disulfide bonds in the crystal. B. Ribbon diagram of Rv3330 structure showing meropenem bound to the catalytic Ser121 (sticks). Cys77, which forms an
intermolecular disulfide bond in the crystals occurs in an N-terminal extension absent from Rv2911. In the domain diagrams, SP denotes the signal peptide,
TM represents the trans-membrane helix, and numbers indicate sequence positions of domain borders. Sequences present in the crystallization constructs
are underlined.
doi:10.1371/journal.pone.0116249.g002
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two-fold axes. Cys100 of Rv2911opt was found in a disulfide with Cys102 from a
symmetry-related molecule. In the Rv3330 crystals, Cys77 residues from adjacent
molecules formed a disulfide across a two-fold axis. Of the four mutations in
Rv2911opt, two, A113V and T197I, were buried, while the other two, N208D and
G289D, were exposed and participated in a crystal contacts.
Both enzymes crystallized with covalently bound active-site inhibitors.
Rv2911opt was bound to a molecule of the nonspecific inhibitor, PMSF, carried
over from the purification. Rv3330 was bound to meropenem, a beta-lactam
Table 1. Data collection and refinement statistics.
Rv2911-PMSF Rv3330-Meropenem
Data Collection
Wavelength (A˚) 0.980 1.116
Temperature (K) 100 100
Space group H 32 P 41 2 2
Cell parameters
a b c (A˚) 75.13 75.13 230.44 76.291 76.291 99.978
a b c (˚) 90 90 120 90 90 90
Copies per a.s.u. 1 1
Resolution (A˚)a 43.13-2.00 (2.07-2.00) 50.0 – 2.00 (2.07-2.00)
Rsym (%) 16 (56.7) 9.5 (80.4)
I/sI 7.7 (3.8) 19.9 (3.4)
Completeness (%) 99.8 (100) 100 (100)
Redundancy 14.9 (11.2) 14.0 (13.9)
Refinement
Resolution (A˚) 43.13 – 2.00 47.48-2.00
Number of reflections 32,821 20,595
Rwork/Rfree (%) 17.3/19.9 18.35/21.04
Number of atoms
Protein 1929 2214
Ligand 16 26
Solvent 150 144
B factors
Protein (A˚2) 23.14 33.10
Ligand (A˚2) 22.7 43.10
Solvent (A˚2) 29.74 37.70
RMSD
Bond lengths (A˚) 0.007 0.012
Bond angles (˚) 1.1 0.99
Ramachandran plot
Favored (%) 97 100
Outliers (%) 0 0
PDB ID 4P0M 4PPR
aValues in parentheses refer to the high-resolution shell.
doi:10.1371/journal.pone.0116249.t001
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antibiotic that was added prior to crystallization (Fig. 3). The active sites of both
proteins contain the three typical penicillin-binding protein motifs: SXXK, SXN,
and KTG. In both structures, the inhibitors were covalently linked to the serine of
the first motif (STIK in Rv2911, SVIK in Rv3330). Residues of the other two
motifs (SGN and KTGY in both proteins) interacted with the bound ligands. A
common feature of both enzyme-inhibitor complexes is the interaction of either
the carboxyl oxygen of meropenem or one of the sulfonyl group oxygens of PMSF
with the oxyanion hole formed by the main-chain amides of the catalytic serine
and the tyrosine of the third motif.
In the Rv2911opt-PMSF structure the conformation of the inhibitor was not
unique, and the electron density for the phenyl group of the ligand suggested at
least two alternate conformations. Neither conformation appeared stabilized by
additional enzyme-inhibitor interactions (Fig. 3A). In contrast, upon binding to
Rv3330, the meropenem molecule assumed a single conformation, as demon-
strated by a well-defined electron density envelope extending away from the active
site (Fig. 3B). This unique conformation is stabilized by several key interactions.
First, the alanine-like moiety within meropenem is hydrogen bonded to Thr283
through the carboxyl and to Ser176 through both the carboxyl and amide groups.
This interaction mimics the contacts made by the D-alanine leaving group of the
natural pentapeptide substrate. Second, the sulfur of the thioester group packs
against the main-chain atoms of Tyr284, with distances of approximately 3.7 A˚ to
the nitrogen, oxygen, and the Cß atoms. Third, the p-system of the distal
carbamoyl moiety participates in a stacking interaction with the phenyl ring of
Tyr284. Finally, the oxygen of the carbamoyl group is hydrogen bonded to Asn291
and Arg313, two residues outside of the canonical active site motifs that are
nonetheless universally conserved among mycobacterial orthologs of Rv3330.
To determine whether the catalytic domains bind polymerized peptidoglycan,
we performed pull-down experiments with peptidoglycan from B. subtilis, which
has a chemotype similar to peptidoglycan from Mtb. In contrast to hen egg-white
lysozyme, a positive control that was retained in the peptidoglycan fraction, both
Fig. 3. Conserved arrangement of catalytic-site residues of Rv2911 and Rv3330 peptidases. A. Rv2911opt-PMSF. Electron-density (2Fo-Fc, 2.0-A˚
resolution, 1s) shows the inhibitor adopts two major conformations (purple and magenta). B. Rv3330-meropenem. Electron-density (2Fo-Fc, 2.0-A˚
resolution, 1s) supports a unique model with extended interactions between the inhibitor (purple) and the enzyme. Common catalytic residues are colored
green and Clade 2 conserved residues in Rv3330 are colored blue.
doi:10.1371/journal.pone.0116249.g003
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Rv2911 and Rv3330 catalytic domains were found primarily in the soluble fraction
(Fig. 4). This weak binding to peptidoglycan may reflect a requirement for
additional protein-protein or protein-membrane interactions to properly localize
and orient these peptidases relative to the substrate.
To determine the subset of residues that underpin penicillin-binding protein
specialization, we constructed multiple sequence alignments of Clade 1 and Clade
2 proteins and mapped the conservation scores onto the protein surfaces (Fig. 5,
A and C). To aid the interpretation of the observed differences, we overlaid
peptidoglycan-mimicking ligands from E. coli PBP6 (PDB 3ITB) and B. subtilis
PBP4a (DacC, PDB 2J9P) structures onto the Mtb peptidase surfaces (Fig. 5, B
and D). Residues predicted to distinguish the stem-peptide meso-DAP, including
Thr234, Leu166, and Asp99 (Rv2911 sequence numbering), are conserved across
the two clades along with the catalytic center residues.
In contrast, clade-specific surface residues surround the catalytic centers of both
enzymes. In Rv2911, these characteristic residues include the 100-CysAsnCys-102
triad on one edge of the catalytic site, as well as Gln216 on an adjacent side. The
equivalent motifs in Rv3330 are 152-GlyThr-153 and Asp268, respectively. In
addition, the extended meropenem-binding site of Rv3330 is distinct from that
occupied by the donor peptide (Fig. 5D). Away from the active site of Rv3330, a
surface region that centers on the loop containing 116-ArgHisArg-118 is
conserved only in Clade 2 (Fig. 5C). This conserved surface measures
approximately 300 A˚2 and participates in a crystal contact that includes the
intermolecular disulfide bond. The conservation of this area could indicate an
interaction site with other proteins or with cell-wall constituents.
Discussion
Investigation of mycobacterial peptidoglycan biology can potentially lead to
improvements to current anti-TB therapies. The recent suggestion that a
Fig. 4. Rv2911 and Rv3330 catalytic domains bind weakly to peptidoglycan in vitro. SDS-PAGE of
control (C), supernatant (S), and peptidoglycan fractions (P) following pull-down with B. subtilis peptidoglycan.
Hen egg lysozyme (HEL) and bovine serum albumin (BSA) were used as positive and negative controls,
respectively. The left lane contains molecular marker in kDa units.
doi:10.1371/journal.pone.0116249.g004
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combination of meropenem with clavulanate can be effective at treating drug-
resistant TB [5] has spurred interest in Mtb penicillin-binding proteins and L,D-
transpeptidases. The latter enzymes were previously thought to be insensitive to
beta-lactams, but Cordillot et al. showed robust inhibition of four out of five Mtb
L,D-transpeptidases by four carbapenems, including meropenem [11]. The
realization that broad target specificity can mediate drug potency [17] intensifies
the need to understand carbapenem recognition by different target families. Here,
we presented structural and phylogenetic analyses of two meropenem-sensitive
Mtb penicillin-binding proteins, Rv2911 and Rv3330.
Poor solubility often constitutes a major challenge to structural and
biochemical characterization of cell wall-associated enzymes. In this study,
Fig. 5. Different conserved surfaces surround the catalytic site in Clade 1 and Clade 2 D,D-
carboxypeptidases. A. Surface representation of Rv2911opt-PMSF showing regions conserved across the
two clades (green, 100% identity) as well as clade-specific conserved surfaces (orange, at least 90% identity
within Clade 1). Surfaces corresponding to residues in the three conserved active site motifs are labeled to
establish orientation. B. Catalytic site of Rv2911 (colored as in A) showing the superposition of stem-peptide
mimicking ligands from E. coli PBP6 (tan, PDB 3ITB) and B. subtilis PBP4a (light blue, PDB 2J9P). The site
that distinguishes lysine (tan) from DAP (light blue) is conserved at the bottom of the figure. PMSF was
omitted for clarity. C. Rv3330-meropenem surface representation showing surfaces conserved across the two
clades (green) and across Clade 2 (blue, at least 90% identity within Clade 2). A large surface (300 A˚2) on the
lower right in the figure is conserved in Clade 2 enzymes. D. The catalytic site of Rv3330 bound to
meropenem (purple) with stem-peptide mimics from the superimposed complexes of E. coli PBP6 (tan, PDB
3ITB) and B. subtilis PBP4a (light blue, PDB 2J9P). The donor-peptide mimic (tan) exits the active site to the
upper left of the figure. In contrast, meropenem interacts with a surface conserved in Clade 2 (upper right).
doi:10.1371/journal.pone.0116249.g005
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structure determination of wild-type Rv2911 protein could not be achieved. To
overcome this challenge, we utilized an unbiased directed-evolution approach.
Four point mutations discovered using directed evolution and the GFP folding
reporter method resulted in the Rv2911opt protein, which showed improved
solubility and allowed crystallographic structure determination. Application of
directed evolution methods to cell-wall associated proteins can aid research
progress in this important area.
Structural analysis can be used to interpret biochemical observations such as
Rv2911 and Rv3330 specificity for DAP-containing stem peptides. Based on
superposition with structures of E. coli [18] and B. subtilis [19] penicillin-binding
proteins bound to stem-peptide mimics we infer that the conserved SGN motif of
the Mtb enzymes forms hydrogen bonds to the proximal carboxyl of DAP.
Binding of the aliphatic middle part of the DAP residue occurs in a narrow groove
that extends away from the catalytic serine between the side chains of conserved
Thr234/286 (Rv2911/Rv3330) and Leu166/218. It is likely that a conserved Glu99/
151 binds to the DAP amide group. The main-chain amides of residues in the
loop that follows the KTGY b-strand are positioned to interact with the distal
DAP carboxyl. In contrast to these shared features of the DAP-binding site, the L-
Ala and iso-D-Gln residues of the superimposed stem peptide are positioned to
interact with clade-specific 100-CysAsnCys-102 in Rv2911 and 152-GlyThr-153 in
Rv3330.
The structure of the meropenem adduct of Rv3330 provides insights into the
interactions of this inhibitor with the target enzyme. The beta-lactam core of
meropenem interacts with the three characteristic penicillin-binding protein
active-site sequence motifs. In contrast, the distal end of this inhibitor, which is
variable in carbapenems, points away from the stem peptide-binding site (Fig. 5).
The meropenem distal end binds a surface that is partially varied between Rv2911
and Rv3330. This binding mode explains the meropenem inhibition of these
enzymes and suggests that the distal interactions of the drug could be exploited to
mediate selectivity.
The phylogenetic analysis of the Peptidase_S11 family proteins shows not only
that Actinobacteria contain a set of penicillin-binding proteins different from that
of Proteobacteria or Firmicutes, but also that gene duplication and specialization
in mycobacteria produced two clades represented by Rv2911 and Rv3330. These
proteins lack the characteristic PBP5 C-terminal domain that is widespread in
both Proteobacteria and Firmicutes, supporting their classification as class 7
penicillin-binding proteins. This analysis contradicts the view that Rv3330 is a
class 5 penicillin-binding protein [9]. The clade-specific residues in Rv2911 and
Rv3330 define sequences that can mediate functional specializations.
The Rv2911opt and Rv3330 inhibitor-complex structures provide a basis to
interpret adaptations that occurred in the two peptidase subfamilies. Importantly,
unlike comparisons of penicillin-binding proteins from different species, the
Rv2911 and Rv3330 comparison excludes the possible effects of differences in
peptidoglycan chemotype or other cell-wall features. Key subfamily adaptations
include clade-specific residues surrounding the catalytic center. In addition,
Mtb Peptidoglycan Peptidases Rv2911 and Rv3330
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Rv3330 contains an extended conserved surface located away from the active site,
and a conserved trans-membrane helix. These features suggest that the two
peptidases could have distinct catalytic activities, different protein partners, or
different modes of interaction with cell-wall polymers. In model organisms,
penicillin-binding proteins interact with other peptidoglycan hydrolases and with
dedicated regulatory proteins [20]. These interactions are critical to the functions
of the cell wall remodeling complexes, including divisome and elongasome
complexes that are responsible, respectively, for daughter cell separation and cell
growth [21]. Discovery of peptidoglycan-processing complexes of Mtb as well as
detailed biochemical analysis of substrate specificity should help reveal the overall
logic of Mtb cell-wall homeostasis and point out the vulnerabilities that can be
attacked by novel and updated drugs.
Materials and Methods
Bioinformatic analyses
Sequences of Peptidase_S11 (PF00768) family proteins from Actinobacteria
(taxid:1760) and Mycobacteria (taxid:1763) were downloaded from the Pfam
server [22]. Sequences of homologous proteins from E. coli and B. subtilis were
obtained from the UniProt database. Alignment of protein sequences truncated to
the Peptidase_S11 catalytic domain were generated with the hmmalign program,
part of the HMMER package [23]. Belvu multiple-alignment editor was used to
discard columns in the alignment that contained greater than 50% gap characters.
Thereafter, redundant rows and rows containing more than 30% gaps were also
removed. The edited alignment was analyzed using the PHYLIP package. The
neighbor-joining tree of all actinobacterial and the maximum-likelihood tree of
the selected mycobacterial proteins were generated using default parameters with
100 bootstrap replicates. The trees were analyzed and rendered using the FigTree
program.
Clade 1 and Clade 2 proteins were gathered using BLAST search against
mycobacterial genomes (taxid:1763) with either Rv2911 (Clade 1) or Rv3330
(Clade 2) as query. The BLAST results were first filtered based on percent query
coverage (95% minimum) and then based on presence of Clade 2 characteristic
transmembrane domains using TMHMM [24]. N-terminal signal peptide
sequences were removed to generate predicted mature forms using the Signal-P
web server [25], keeping the trans-membrane sequences intact. Alignments of
clade-assigned sequences were generated using the MUSCLE program [26].
Construct design, cloning, and protein purification
Maximal constructs matching the predicted mature forms were used: 26–291 for
Rv2911 and 38–368 for Rv3330. This Rv3330 construct stopped at the beginning
of the predicted C-terminal trans-membrane domain. The two genes were cloned
from Mtb strain H37Rv genomic DNA into pDEST15 vector using the Gateway
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system (Invitrogen). Rosetta 2(DE3) E. coli expression cells (Novagen)
transformed with GST-tagged TEV-cleavable constructs were inoculated into
Terrific Broth, grown to OD600 of 0.6, and induced with 0.2 mM IPTG. Cells were
grown with shaking at room temperature for 18 hours and harvested by
centrifugation. Cell pellets were resuspended in 300 mM NaCl, 20 mM HEPES,
pH 7.5, 0.5 mM TCEP, 10% glycerol and lysed by sonication at 4 C˚. Lysates were
cleared by centrifugation and filtration using 0.22 mm filters. Samples were
applied to equilibrated glutathione-affinity columns (GE), washed and then eluted
with 20 mM reduced glutathione (Sigma) in the above buffer. Overnight dialysis
into the glutathione-free buffer was performed following addition of 0.5 mg of
TEV protease. Glutathione-affinity chromatography was repeated to remove the
GST tag. Size-exclusion chromatography on a Superdex-75 column (GE) was used
to complete purification. The proteins were used in peptidoglycan-binding assays
and to obtain crystals of Rv3330. The Rv2911 construct used for crystallization,
however, required extensive optimization as described below.
Rv2911 cloning and construct optimization by directed evolution
and the GFP folding reporter method
Full-length wild-type Rv2911, including a predicted leader sequence, was
expressed from pET28 vector in E. coli BL21(DE3) cells at either 27 C˚ or 37 C˚ and
was insoluble. The wild-type Rv2911 was subjected to forward evolution using the
GFP folding reporter method [16]. During each round of evolution, 40 brightest
colonies out of approximately 40,000 were picked for subsequent recombination
by gene shuffling [16, 27]. After four rounds of forward evolution, there was no
further increase in GFP fusion fluorescence. Following two rounds of back-
crossing, the optimized sequence contained C12R, V18D, A113V, T197I, N208D,
and G289D mutations. Because the soluble full-length protein failed to yield
diffraction-quality crystals, an N-terminal truncation lacking 16-residue leader
sequence was used.
Rv2911opt protein purification
E. coli BL21(DE3) cells transformed with C-terminally His-tagged Rv2911opt
expression plasmid were grown to OD600 of 0.6 and induced with 1 mM IPTG.
Growth was continued at 22 C˚ for 20 hours. The cell pellets were resuspended in
buffer A (20 mM Tris, pH 8.0, 100 mM NaCl, protease inhibitor cocktail) and
lysed by sonication. After ultracentrifugation for 30 min at 38,000 rpm, the
supernatant was loaded on a 5 mL Talon superflow affinity column (Clontech)
equilibrated with buffer A. After washing with 30 mL buffer A, the His-tagged
Rv2911opt was eluted from the Talon affinity column using buffer B (20 mM Tris,
pH 8.0, 100 mM NaCl, 300 mM imidazole). The eluted fraction was dialyzed
against buffer A and purified by gel filtration on a Superdex-75 column
(Amersham Pharmacia Biotech) using buffer A with 10 mM b-mercaptoethanol
for equilibration and elution. Selenomethionyl Rv2911 was prepared using
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methionine pathway inhibition method [28] by growing cells in presence of
60 mg/L L-Se-Met with additional 100 mg/L of threonine, lysine and phenyla-
lanine each, and 50 mg/L of isoleucine, leucine and valine each. Mass spectro-
metry (Applied Biosystems) was used to confirm, that all 7 Met residues were
replaced by Se-Met.
Structure of Rv2911opt
Rv2911opt crystals were obtained by mixing protein (15 mg/ml) 1:1 with the
mother liquor (17% PEG monomethyl ester 5000, 0.15 M Ammonium sulfate, 0.1
M Citrate buffer pH 5.6) in hanging-drop format at 22 C˚. The three-wavelength
multiwavelength anomalous diffraction data of Rv2911opt SeMet crystal were
collected at Beamline 5.0.2 of the Advanced Light Source (ALS) at Lawrence
Berkeley National Laboratory (LBNL), and processed with the HKL2000 package
[29]. The structure was determined with SHELX [30] and the model was partially
traced by RESOLVE [31] after solvent flattering with DM [32] in CCP4 package
[33]. Tracing was completed with Arp/wArp [34]. PMSF moiety covalently linked
to Ser69 was traced manually using SEB (o-benzylsulfonyl-serine) residue from
PDB entry 1ZIY as a starting model. The program Coot [35] was used for manual
rebuilding. Refinement was carried out using the program Phenix [36]. The
structure has been deposited to the Protein Data Bank under accession number
4P0M.
Structure of Rv3330
Rv3330 (10 mg/ml) was incubated with a two-fold molar excess of meropenem
(Sigma) for 30 min and mixed 1:1 with 0.1 M NaCl, 0.1 M HEPES, pH 7.23, 1.7
M ammonium sulfate well solution in a hanging-drop format. The crystals were
cryopreserved in 20% xylitol in well solution and frozen in liquid nitrogen. X-ray
diffraction data were collected under cryogenic conditions at Beamline 8.3.1 at the
ALS at LBNL [37] and processed using HKL2000 [29]. The structure was
determined by molecular replacement using the Rv2911opt coordinates as the
search model. Molecular replacement, model building, refinement, and validation
were performed using Phenix [36] and Coot [35]. The structure has been
deposited to the Protein Data Bank under accession number 4PPR. Molecular
images were generated using Chimera [38].
Peptidoglycan binding assay
One milligram of B. subtilis peptidoglycan (Sigma) was washed twice in 1 ml of
pure water and resuspended in 100 ml of binding buffer (150 mM NaCl, 25 mM
HEPES, pH 7). Protein samples (10 ml at 0.4 mg/ml) were added to 10 ml of
peptidoglycan suspension, mixed, and incubated for 5 min at room temperature
with nutation. Samples were centrifuged for two minutes at 11,500 g. Input
control, bound, and free protein fractions were analyzed by SDS-PAGE and
stained with Coomassie Brilliant Blue (Bio-Rad).
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